Overview

Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)

Status:
Not yet recruiting

Trial end date:
2028-04-01

Target enrollment:

Participant gender:

Summary

This trial studies the combination of low-dose PCI with or without durvalumab in patients with radically treated stage III NSCLC. The hypothesis is that the incidence of brain metastases will be reduced from 30% to 15 % with durvalumab and to a maximum of 5% with the addition of low-dose PCI. This strategy would make brain metastases in stage III NSCLC history and this would improve QoL.

Phase:

Phase 3

Details

Lead Sponsor:

Association NVALT Studies

Treatments:

Durvalumab